Jan-15-21 Resumed
BofA Securities
Buy
$35
Jun-24-20 Initiated
H.C. Wainwright
Buy
$41
Apr-28-20 Initiated
Goldman
Buy
$32
Mar-06-20 Initiated
Citigroup
Buy
$40
Feb-27-20 Initiated
Barclays
Overweight
$36
Feb-19-20 Initiated
Stifel
Buy
$44
Nov-21-19 Initiated
BTIG Research
Buy
$28
Mar-04-19 Initiated
SVB Leerink
Outperform
Mar-04-19 Initiated
Morgan Stanley
Overweight
$27
Mar-04-19 Initiated
BofA/Merrill
Buy
$26
Mar-04-19 Initiated
Barclays
Overweight
$27
Mar-30-21 01:23PM
Mar-25-21 04:05PM
Mar-23-21 01:53PM
Mar-04-21 04:05PM
Feb-28-21 01:36AM
Feb-25-21 04:05PM
Jan-25-21 08:30AM
Jan-20-21 04:15PM
Jan-07-21 04:05PM
Dec-29-20 11:42PM
Dec-11-20 08:56AM
Nov-12-20 11:18AM
Nov-11-20 04:05PM
Nov-10-20 06:45PM
04:05PM
Nov-09-20 05:30AM
Nov-03-20 12:30PM
Nov-02-20 07:44AM
Oct-22-20 04:05PM
Oct-06-20 08:54AM
Sep-24-20 11:46AM
Sep-16-20 03:23PM
Sep-13-20 08:53AM
Sep-03-20 04:05PM
Aug-11-20 05:55PM
04:05PM
Aug-04-20 08:30AM
Aug-03-20 12:31PM
Jul-29-20 01:00PM
07:32AM
Jul-28-20 06:00PM
Jul-24-20 06:12PM
08:30AM
Jul-21-20 05:00PM
05:00PM
Jul-15-20 07:31AM
Jun-28-20 07:16PM
Jun-25-20 09:00AM
Jun-12-20 07:00PM
Jun-03-20 04:01PM
May-16-20 08:05AM
May-13-20 09:25AM
08:00AM
May-07-20 08:30AM
May-04-20 08:20AM
May-03-20 07:00AM
Apr-02-20 11:30AM
Mar-31-20 10:34AM
Mar-26-20 06:11AM
Mar-25-20 05:00PM
Mar-24-20 05:25PM
04:05PM
Mar-23-20 08:30AM
Mar-17-20 12:30PM
12:00PM
11:30AM
Mar-11-20 09:53AM
Mar-06-20 07:25PM
Feb-28-20 08:51AM
Feb-24-20 08:30AM
Feb-06-20 07:47AM
Feb-05-20 08:00AM
07:21AM
Feb-03-20 06:00PM
Jan-31-20 09:09AM
08:00AM
Jan-29-20 09:42PM
Jan-28-20 08:30AM
Jan-27-20 04:05PM
Jan-17-20 08:45PM
Jan-08-20 08:30AM
Jan-06-20 08:30AM
Dec-27-19 02:57PM
Dec-20-19 08:30AM
Dec-13-19 06:30AM
06:28AM
Dec-12-19 07:08PM
Dec-11-19 04:05PM
Dec-06-19 04:30PM
07:39AM
Dec-05-19 04:22PM
Dec-04-19 09:15AM
Nov-14-19 08:30AM
Nov-12-19 04:05PM
Nov-11-19 09:28AM
Oct-28-19 07:46PM
Sep-23-19 01:22PM
Sep-20-19 10:02AM
Sep-19-19 06:56AM
Sep-09-19 08:00AM
Sep-03-19 04:10PM
Aug-12-19 04:10PM
09:00AM
Jul-18-19 10:26AM
Jul-17-19 04:05PM
Jul-11-19 06:30AM
Jun-26-19 09:04PM
Jun-14-19 12:03PM Investor's Business Daily
May-13-19 04:26PM
04:05PM
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies. The company was founded in 2013 and is headquartered in South San Francisco, California.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Paul Robert Chief Medical Officer Apr 07 Option Exercise 9.60 22,300 214,186 236,019 Apr 08 08:18 PM Paul Robert Chief Medical Officer Apr 07 Sale 19.20 22,300 428,050 213,719 Apr 08 08:18 PM Paul Robert Chief Medical Officer Mar 23 Option Exercise 8.16 13,800 112,608 227,519 Mar 24 04:36 PM Paul Robert Chief Medical Officer Mar 23 Sale 22.21 13,800 306,498 213,719 Mar 24 04:36 PM Paul Robert Chief Medical Officer Mar 22 Option Exercise 8.16 30,000 244,800 243,719 Mar 24 04:36 PM Paul Robert Chief Medical Officer Mar 22 Sale 22.98 30,000 689,376 213,719 Mar 24 04:36 PM Paul Robert Chief Medical Officer Mar 09 Option Exercise 8.38 19,175 160,592 232,894 Mar 10 06:29 PM Paul Robert Chief Medical Officer Mar 09 Sale 18.12 19,175 347,405 213,719 Mar 10 06:29 PM Paul Robert Chief Medical Officer Feb 09 Option Exercise 8.38 19,175 160,594 232,894 Feb 11 05:08 PM Paul Robert Chief Medical Officer Feb 09 Sale 20.81 19,175 399,055 213,719 Feb 11 05:08 PM Paul Robert Chief Medical Officer Jan 26 Option Exercise 8.46 27,308 231,082 241,027 Jan 27 06:53 PM Paul Robert Chief Medical Officer Jan 26 Sale 18.00 27,308 491,544 213,719 Jan 27 06:53 PM Paul Robert Chief Medical Officer Jan 25 Option Exercise 8.30 30,000 248,926 243,719 Jan 27 06:53 PM Paul Robert Chief Medical Officer Jan 25 Sale 18.01 30,000 540,225 213,719 Jan 27 06:53 PM Paul Robert Chief Medical Officer Jan 20 Option Exercise 8.64 8,567 74,031 222,286 Jan 21 06:46 PM Paul Robert Chief Medical Officer Jan 20 Sale 18.00 8,567 154,211 213,719 Jan 21 06:46 PM Paul Robert Chief Medical Officer Jan 19 Option Exercise 8.30 30,000 248,924 243,719 Jan 21 06:46 PM Paul Robert Chief Medical Officer Jan 19 Sale 18.12 30,000 543,552 213,719 Jan 21 06:46 PM Paul Robert Chief Medical Officer Jul 15 Sale 22.96 10,000 229,642 213,719 Jul 17 04:43 PM MCGUIRE TERRANCE Director Jun 23 Sale 31.54 4,377 138,063 12,853,817 Jun 25 05:53 PM Polaris Venture Management Co. 10% Owner Jun 23 Sale 31.54 4,377 138,063 12,853,817 Jun 25 05:47 PM Paul Robert Chief Medical Officer Jun 15 Sale 29.61 10,000 296,137 223,719 Jun 17 04:21 PM Yu Calvin Vice President, Finance Jun 03 Sale 31.26 1,343 41,981 110,686 Jun 05 04:40 PM King Robert Chief Development Officer May 15 Sale 27.00 15,000 404,958 477,317 May 19 05:23 PM Paul Robert Chief Medical Officer May 15 Sale 27.00 10,000 270,026 233,719 May 19 05:23 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite